PCRX Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenue: Increased by 6% year-over-year, reaching $175.4 million.
EXPAREL Sales: $139.9 million, up from $132.0 million in Q3 2024, with a volume growth of 9%.
Zilretta Sales: $29.0 million, slightly up from $28.4 million in Q3 2024.
Iovera Sales: Grew to $6.5 million from $5.7 million in Q3 2024.
Gross Margin: Non-GAAP gross margin improved to 82% from 78% year-over-year.
Adjusted EBITDA: Reported at $49.4 million for the quarter.
Cash and Investments: Approximately $246 million at quarter-end.
Share Repurchases: $50 million executed during the quarter.

2. Strategic Updates and Business Highlights

5x30 Growth Strategy: Focus on expanding the commercial base and advancing an innovative pipeline, including the in-licensing of AMT-143, a long-acting non-opioid.
EXPAREL Demand: Strong growth attributed to improved market access, partnerships, and promotional efforts, with expectations to surpass 100 million covered lives.
Zilretta and Iovera: New initiatives and partnerships (e.g., with Johnson & Johnson MedTech) are expected to enhance growth.
Clinical Pipeline: PCRX-201 is advancing in a Phase II study for osteoarthritis, with positive early feedback and enrollment ahead of schedule.

3. Forward Guidance and Outlook

Revenue Guidance: Increased to $725 million to $735 million for 2025.
Gross Margin Guidance: Adjusted to 80% to 82%, reflecting improved manufacturing efficiencies.
R&D and SG&A Expenses: Non-GAAP R&D expense guidance set at $95 million to $105 million; SG&A expense guidance narrowed to $310 million to $320 million.
Future Growth: Anticipated convergence of volume and revenue growth as GPO agreements anniversary.

4. Bad News, Challenges, or Points of Concern

Zilretta Growth: Slower than anticipated, with challenges in adoption despite new partnerships.
Discounting Impact: Recent GPO agreements have led to a shift in vial mix and discounting, affecting ASP and revenue growth.
Market Conditions: Elective procedure growth remains sluggish, impacting overall market dynamics.
Competitive Pressures: Ongoing Paragraph IV notifications regarding potential generic competition for EXPAREL.

5. Notable Q&A Insights

GPO Impact: Strong uptake from GPOs is expected to improve revenue as agreements anniversary, with anticipated narrowing of the gap between volume growth and revenue.
Market Awareness: Increased awareness of NOPAIN initiatives in larger hospitals is progressing, but adoption may take longer due to more decision-makers involved.
AMT-143 Development: Positioned as a complementary product to EXPAREL, with a focus on longer duration pain relief and ease of administration.
Feedback on PCRX-201: Positive enthusiasm from physicians, but ongoing education is needed to address skepticism around gene therapy, particularly in orthopedics.

Overall, Pacira BioSciences reported a solid quarter with strong revenue growth driven by EXPAREL, while also facing challenges in Zilretta's growth and market dynamics. The company remains focused on executing its strategic initiatives and enhancing its product pipeline.

PCRX — Pacira BioSciences, Inc.